Maxkos Pharmaceuticals Private Limited
Founded in 2007 and headquartered in Maharashtra, India.
2007 | Solapur, Maharashtra (India) | Active
Maxkos Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.36 M
- Company Age 17 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 55.07%
- Profit Growth 218.03%
- Ebitda 254.61%
- Net Worth -13.82%
- Total Assets 2.37%
About Maxkos Pharmaceuticals
Maxkos Pharmaceuticals Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 April 2007 and has a history of 17 years and ten months. Its registered office is in Solapur, Maharashtra, India.
The Corporate was formerly known as Maxkos Pharmaceuticals & Softwares Private Limited. The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.36 M, as per Ministry of Corporate Affairs (MCA) records.
Kashinath Patil and Uma Patil serve as directors at the Company.
Company Details
- Location
Solapur, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24239PN2007PTC130031
- Company No.
130031
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Apr 2007
- Date of AGM
17 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Chemicals
Who are the key members and board of directors at Maxkos Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kashinath Patil  | Director | 24-Apr-2007 | Current |
| Uma Patil | Director | 24-Apr-2007 | Current |
Financial Performance of Maxkos Pharmaceuticals.
Maxkos Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 55.07% increase. The company also saw a substantial improvement in profitability, with a 218.03% increase in profit. The company's net worth observed a substantial decline by a decrease of 13.82%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Maxkos Pharmaceuticals?
In 2017, Maxkos Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Maxkos Pharmaceuticals?
Unlock and access historical data on people associated with Maxkos Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Maxkos Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Maxkos Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.